The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

To demonstrate that RBC saturation of the Omega-3 fatty acids reaching cardioprotective levels as proven with the HS-Omega-3 Index test will be achieved most efficiently depending on a specific product utilized within this study.

Approximately 2240 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.

Active Comparator: Nature's Made

2 capsules per day = 2400mg Omega-3s

Dietary Supplement: Omega-3

Approximately 2400 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.

Active Comparator: Thera Tears

4 capsules per day = 2332mg Omega-3s

Dietary Supplement: Omega-3

Approximately 2332 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.

Detailed Description:

To demonstrate that RBC saturation of the Omega-3 fatty acids reaching cardioprotective levels as proven with the HS-Omega-3 Index test will be achieved most efficiently depending on a specific product utilized within this study. The HS-Omega-3 Index is a new test that measures blood levels of the cardioprotective omega-3 fatty acids, EPA and DHA. RBS saturation is being measured to identify how much Omega 3 is in the blood.

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion Criteria:

Willing and able to give written informed consent.

Subject motivation and willingness to cooperate with the investigator by following the required medication regimen.

Subject willingness and ability to return for all visits during the study.

Must be willing to discontinue all use of Omega-3 supplementation 2 weeks prior to study participation.

Exclusion Criteria:

Concurrent involvement in any other clinical trial involving an investigational drug or device.

Compromised cognitive ability which may be expected to interfere with study compliance.

Uncontrolled or poorly controlled systemic disease ot the presence of any significant illness that could, in the judgment of the investigator, jeopardize subject safety or interfere with the interpretation of the results of the study.

Subjects must not eat more that 1 non-fried fish meal per week.

Subjects must not have undergone any bariatric surgery or have a malabsorption disorder.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01091714